ClinicalTrials.gg
Not yet recruitingNCT07942792DiamondUpdated Nov 17, 2026

Evaluation of Unexplained Severe Syncope in a Modern Syncope Unit

An observational study in Syncope and Collapse, sponsored by Istituto Auxologico Italiano. Not yet recruiting. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Istituto Auxologico Italiano · Observational

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
16 Years and older
Sex
All
01

Study summary

The aim of the present study is to evaluate clinical practice in the diagnosis of severe unexplained syncope among European Syncope Units adhering to the standards set forth by the ESC guidelines.

Read the detailed description

The Diamond study is an investigator-initiated, prospective, international, multicenter study, coordinated by the non-profit organization Gruppo Italiano Studio Sincope (GIMSI), conducted within European Syncope Units that fulfill the personnel and equipment criteria recommended by the European Heart Rhythm Association (EHRA) and the (GIMSI) (https://www.gimsi.it/modello-organizzativo/).

Eligibility of each center is certified by the head of the syncope unit, who completes a questionnaire confirming compliance with the required standards. Web-based Clinical Report Form (CRF). To allow uniform clinical data collection from participating centres, a web-based CRF, was designed Study workflow. Following documented patient consent, clinical personnel at the site -trained in the use of the web-app- will access the digital tool to enter the patient's I/E criteria assessment, personal information and medical history. From that point forward, data will be entered into the web-app on an ongoing basis, in accordance with the site's routine clinical practice, until the patient reaches a defined exit point (such as diagnosis of cardiac syncope, diagnosis of autonomic syncope, no syncope, no diagnosis), or drop-out (e.g., patient death, patient unable to comply with diagnostic pathway, etc.).

02

Conditions studied

  • Syncope and Collapse

Browse trials for

03

In context

Syncope

202 studies on the registry are indexed under Syncope; 37 are open to participants now.

This study's planned enrollment of 300 is above the median of 250 across 85 observational studies indexed under Syncope.

Browse Syncope studies →

Lead sponsor

Istituto Auxologico Italiano is the lead sponsor of 204 studies on the registry; 70 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Consecutive patients referred to the Syncope Unit for severe unexplained syncope

Eligibility criteria

Inclusion Criteria: Outpatients aged ≥16 years referred to the Syncope Unit due to severe, unexplained syncope and/or unexplained fall requiring comprehensive evaluation to identify the most appropriate mechanism-specific therapy.

Exclusion Criteria: Non-severe syncope Definitions.

  • Unexplained syncope is defined as unexplained etiology or unexplained
  • Severe syncope is defined by the presence of one or more among the following:

    1. Suspected life-threatening arrhythmias
    2. Substantial impact on patient's quality of life (QoL)

      • Frequent episodes
      • Restriction of educational or occupational activities (including, but not limited to, unemployment)
      • Restriction of social or daily-life activities, e.g. when syncope occurs while driving
    3. High risk of outcomes

      • Syncope associated with major injuries/trauma, i.e. head injury or fractures
      • Unpredictable syncope, i.e. without prodrome or identifiable triggers
    4. Presence of serious comorbidities, such as concomitant heart disease, neurologic disease, diabetes or renal failure
    5. Suspected Autonomic syncope overlapping with suspected psychogenic pseudosyncope
  • Non-severe syncope is defined by the presence of one or more among the following:

    1. Sporadic (isolated) episodes without major impact on patient's QoL
    2. Predictable syncope, i.e. syncope preceded by prodrome and/or occurring in association with identifiable triggers, with low risk of injuries
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Target follow-up
1 Year
Patient registry
Yes

Groups and cohorts

  • Unexplained syncope

    Syncope Unit

    Diagnostic Test: Standardised guideline-based diagnostic flow-chart

Interventions

  • Diagnostic testStandardised guideline-based diagnostic flow-chart

    At the initial evaluation, it is essential to exclude non-syncopal causes of transient loss of consciousness (TLOC) - such as epilepsy, psychogenic pseudosyncope, and other conditions of apparent loss of consciousness that may be incorrectly diagnosed as syncope. Once non-syncopal causes have been excluded and the loss of consciousness is determined to be syncopal in nature, the primary objective of the diagnostic work-up is to identify cases of cardiac syncope. Cardiac syncope is characterized by loss of consciousness due to a primary cardiac disorder, such as arrhythmias or structural heart disease, and requires prompt recognition and appropriate treatment due to its association with higher morbidity and mortality. When both cardiac syncope and non-syncopal causes of TLOC are reasonably ruled out, the diagnosis of autonomic syncope becomes likely. Autonomic syncope encompasses both reflex (neurally mediated) syncope and orthostatic hypotension and represents the most frequent cause

06

What researchers measure

Primary outcomes

  1. Rate of final diagnoses 2) Type of final diagnoses 3) Number of tests utilized to reach them.

    Time frame: through study completion, an average of 1 year

Secondary outcomes

  1. Number of participants with adherence of the clinical practices to a theoretical diagnostic pathway

    Time frame: through study completion, an average of 1 year

  2. Assessment of number and costs of resource utilization associated to the clinical practices

    Time frame: through study completion, an average of 1 year

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

Of 44 observational studies under Syncope, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 13. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2026
First posted
Nov 17, 2026
StartEst.
Dec 31, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07942792
Collaborators
GRUPPO ITALIANO MULTIDISCIPLINARE PER LO STUDIO DELLA SINCOPE (GIMSI)
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Dec 31, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion